Shares of Kura Oncology Inc. (NASDAQ:KURA) dropped 3.6% during mid-day trading on Wednesday . The stock traded as low as $5.53 and last traded at $5.67, with a volume of 157,674 shares changing hands. The stock had previously closed at $5.88.

KURA has been the subject of several recent research reports. Zacks Investment Research raised Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a report on Wednesday, July 13th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Kura Oncology in a research note on Sunday, August 14th.

The firm’s market capitalization is $110.96 million. The firm has a 50-day moving average price of $4.74 and a 200-day moving average price of $3.77.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.02. On average, equities research analysts forecast that Kura Oncology Inc. will post ($1.58) EPS for the current year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.